News
03-31-2016, 05:12 AM
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency of germline mutations in 25 cancer susceptibility genes among patients with breast cancer.
More... (http://www.news-medical.net/news/20160331/Myriad-myRisk-Hereditary-Cancer-test-identifies-7025-more-deleterious-mutations-than-BRCA12-testing-alone.aspx)
More... (http://www.news-medical.net/news/20160331/Myriad-myRisk-Hereditary-Cancer-test-identifies-7025-more-deleterious-mutations-than-BRCA12-testing-alone.aspx)